Vistagen Therapeutics Faces Class Action Over Fasedienol Communications

Vistagen Faces Class Action Over Fasedienol Communications

Court Motion Looms Over Vistagen’s Fasedienol Program

Rosen Law Firm is pressing potential lead plaintiffs in a class action tied to Vistagen Therapeutics to move the court by March 16, 2026, underscoring renewed legal pressure on the company’s messaging around its investigational pherine, fasedienol. The firm issues its reminder to anyone who purchased Vistagen common stock between April 1, 2024 and December 16, 2025 and notes that appointment of a lead plaintiff — who will direct the litigation on behalf of the class — must be sought by that deadline. Rosen is soliciting clients under a contingency-fee arrangement and is providing multiple avenues for submission.

The complaint alleges Vistagen misled investors about the prospects and operational readiness of its Phase 3 program, PALISADE-3, by relying on the prior PALISADE-2 results and by asserting that trial enhancements and procedural changes materially increase the likelihood of Phase 3 success and support a confirmatory study. Plaintiffs contend those public statements overstated the strength of the underlying data and the certainty of a regulatory pathway, framing the litigation as a challenge to corporate communications around clinical development rather than the science itself.

Beyond potential damages, the litigation raises reputational and programmatic risks for Vistagen’s development pathway for fasedienol, which the company is advancing as an acute treatment for social anxiety disorder. Legal scrutiny of past statements could complicate ongoing trial operations, partner negotiations and regulatory interactions by prompting closer review of trial design disclosures and the company’s public characterizations of interim and prior results.

Rosen Law highlights its record in securities class actions as it seeks representation, citing historical settlements and firm rankings to encourage investors to move quickly in selecting counsel. The firm offers a submission portal and direct contact options for investors considering joining the case.

Fasedienol is an investigational pherine candidate that Vistagen is developing for acute social anxiety disorder. The dispute centers on how the company portrayed PALISADE-2 findings and the purported improvements to PALISADE-3, with plaintiffs asserting those statements gave an inflated view of the likelihood of Phase 3 success and the feasibility of a confirmatory study.